, Volume 4, Issue 2, pp 105–123 | Cite as

Meloxicam: A toxicology overview

  • H. A. Lehmann
  • M. Baumeister
  • L. Lützen
  • J. Wiegleb


Meloxicam is a new potent non-steroidal anti-inflammatory drug (NSAID), which in animal tests exhibits potential antiarthritic action and has a wider spectrum of anti-inflammatory activity than currently available NSAIDs. Toxicological testing of meloxicam in animals suggests that acute oral overdosage is unlikely to cause severe toxicity in man. Compared with other NSAIDs, meloxicam has a relatively weak effect on gastric acid secretion and on ulceration in the rat stomach. Whereas most NSAIDs can cause parenchymal kidney damage in animals at low plasma levels and over relatively short periods, meloxicam only induces such damage in the rat over the longer term. Meloxicam preferentially inhibits cyclooxygenase-2 (COX-2), rather than cyclooxygenase-1 (COX-1), which may explain its good gastric and renal tolerability. Meloxicam was chondroneutral in long-term studies in rats and mice. It was significantly less phototoxic in vitro than diclofenac, ketoprofen and naproxen, but similar to piroxicam and tenoxicam. There was no evidence of mutagenic, clastogenic, teratogenic or tumorigenic activity on immunogenic potential.


gastrointestinal toxicity meloxicam NSAIDs piroxicam toxicology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vane JR. Towards a better aspirin. Nature. 1994;367:215–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Engelhardt G. Meloxicam: A potent inhibitor of COX-2. Abstract presented at the 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, 6–10 June. 1994:82.Google Scholar
  3. 3.
    Goodwin JS, Ceuppens JL Effect of nonsteroidal antiinflammatory drugs on immune function. Semin Arthritis Rheum. 1983;13(1)(Suppl 1):134–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Magnusson B, Kligman AM. The identification of contact allergens by animal assay. The guinea pig maximization test. J Invest Dermatol. 1969;52:268–76.PubMedGoogle Scholar
  5. 5.
    Hurtenbach U, Gleichmann H, Nagate N, Gleichmann E. Immunity of D-penicillamin, genetic, cellular, and chemical requirements for induction of popliteal lymph node enlargement in the mouse. J Immunol. 1987;139:411–16.PubMedGoogle Scholar
  6. 6.
    Figueiredo A, Teixeira E, Poiares-Baptista A. Photosensitivity to nonsteroidal anti-inflammatory drugs. Int J Dermatol. 1989;28:139–40.CrossRefGoogle Scholar
  7. 7.
    Kochevar IE. Phototoxicity of nonsteroidal anti-inflammatory drugs. Coincidence or specific mechanism? Arch Dermatol. 1989;125:824–6.CrossRefGoogle Scholar
  8. 8.
    Schmid J, Busch U, Trummlitz G, Prox A, Kaschke S, Wachsmuth H. Meloxicam (UH-AC 62 XX): metabolic pattern and structure elucidation in rats. Xenobiotica. 1995;25:1219–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. Meloxicam: Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos. 1995;23:1206–13.PubMedGoogle Scholar
  10. 10.
    Kochevar IE, Morison WL, Lamm JL, McAuliffe DJ, Western A, Hood AF. Possible mechanism of piroxicam-induced photosensitivity. Arch Dermatol. 1986;122:1283–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Rainsford KD. Concepts of the mode of action and toxicity of anti-inflammatory drugs. A basis for safer and more selective therapy, and for future developments In: Rainsford KD, Velo GP, eds. New developments in antirheumatic therapy, Vol. III. Lancaster: Kluwer Academic Publishers; 1989:37–92.Google Scholar
  12. 12.
    Dingle JT. NSAIDs and human cartilage metabolism. In: Rainsford KD, Velo GP, eds. Side-effects of Anti-inflammatory Drugs 3: Inflammation and Drug Therapy Series, Vol. V. Dordrecht: Kluwer Academic Publishers; 1992:261–8.Google Scholar
  13. 13.
    Davis MA, Ettinger WH, Neuhaus JM, Mallon KP. Knee osteoarthritis and physical functioning: Evidence from the NHANES I Epidemiologic Follow up Study. J Rheumatol. 1991;18(4):591–8.PubMedGoogle Scholar
  14. 14.
    Kohatsu ND, Schurman DJ. Risk factors for the development of osteoarthritis of the knee. Clin Orthop. 1990;261:242–6.PubMedGoogle Scholar
  15. 15.
    Van Der Kraan PM, Vitters EL, Van De Putte LBA, Van Den Berg WB. Development of osteoarthritic lesions in mice by ‘metabolic’ and ‘mechanical’ alterations in the knee joints Am J Pathol. 1989;135:1001–14.PubMedGoogle Scholar
  16. 16.
    Rainsford KD, Ying C, Gadd S, Ginsburg I. Comparative effects of meloxicam on cellular components of joint injury in vitro. Presented at the 2nd International Congress of the Osteoarthritis Research Society (OARS), Orlando, Florida, USA, 9–11 December, 1994.Google Scholar
  17. 17.
    Engelhardt G. Meloxicam: Comparison of in vitro and in vivo activity. Abstract presented at XVII ILAR Congress of Rheumatology, Rio de Janeiro, Brazil, September 17–23, 1989.Google Scholar
  18. 18.
    Engelhardt G, Homma D, Schnitzler C. Meloxicam: A potent inhibitor of adjuvant arthritis in the rat. Inflamm Res. 1995;44:548–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Wiseman EH. Review of preclinical studies with piroxicam: Pharmacology, pharmacokinetics and toxicology. In: Royal Society of Medicine, International Congress and Symposium Series No. 1. Academic Press Inc (London) and Royal Society of Medicine; 1978:1–23.Google Scholar
  20. 20.
    Crowshaw K. Role of inhibition of prostaglandin biosynthesis by anti-inflammatory drugs in the pathogenesis of renal damage. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs: Advances in Inflammation Research, Vol. 6. New York: Raven Press; 1984:148–59.Google Scholar
  21. 21.
    Crowshaw K. Recent studies on the comparative nephrotoxicity of anti-inflammatory agents. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs 2: Studies in Major Organ Systems. Lancaster: MTP Press; 1987:357–66.Google Scholar
  22. 22.
    Kimberly RP. Anti-inflammatory drugs and the kidney in systemic lupus erythematosus and other arthropathies: ‘Set-point’ modulation of renal function. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs: Advances in Inflammation Research, Vol. 6. New York: Raven Press; 1984:119–28.Google Scholar
  23. 23.
    Wiseman EH, Reinert H. Anti-inflammatory drugs and renal papillary necrosis. Agents Actions. 1975;5:322–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Guess HA, West R, Strand LM et al. Hospitalizations for renal impairment among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan, Canada, 1983. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs, Vol. 2. Lancaster: MTP Press Ltd; 1987:2367–75.Google Scholar
  25. 25.
    Prescott LF, Martin U. Current status of nephrotoxicity caused by non-steroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs 3, Inflammation and Drug Therapy Series, Vol. V. Dordrecht: Kluwer Academic Publishers; 1992:223–5.Google Scholar
  26. 26.
    Prescott LF. Renal damage in man from ingestion of anti-inflammatory and analgesic drugs. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs, Advances in Inflammation Research, Vol. 6. New York: Raven Press; 1984:109–17.Google Scholar
  27. 27.
    Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. J Am Med Assoc. 1990;264:471–5.CrossRefGoogle Scholar
  28. 28.
    Mavrikakis ME, Georgilis KA, Ziroyannis PN, Kehayoglou KA, Moulopoulos SD. Piroxicam-induced acute renal failure (anuria). Ann Rheum Dis. 1985;44:356.PubMedCrossRefGoogle Scholar
  29. 29.
    Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med. 1990;112:568–76.PubMedGoogle Scholar
  30. 30.
    Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993;90:11693–7.PubMedCrossRefGoogle Scholar
  31. 31.
    De Witt DL, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med. 1993;95(Suppl 2A):40S-5S.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • H. A. Lehmann
    • 1
  • M. Baumeister
    • 1
  • L. Lützen
    • 1
  • J. Wiegleb
    • 1
  1. 1.Dr Karl Thomae GmbHBiberach an der RissGermany

Personalised recommendations